CD226 and neoplasm: In 2018, Zhigang Tian lab found that the blockade of TIGIT reversed the exhaustion of tumor-infiltrating NK cells, increased the frequency of tumor-infiltrating NK cells expressing CD107a, tumor necrosis factor, interferon-γ, and CD226.